Table 5.
Estimated costs and benefits of neonatal eye screening project
| Disease | ① Total number of patients detected by our procedure | ② Estimated average cost for treatment after early detection [CNY (US dollars)] | ③ Average cost for treatment with delayed detection (CNY (US dollars)) | ④ Direct medical benefit (①*（③ − ②)) [CNY (US dollars)] | ⑤ Estimated rate of blindness | ⑥ Number of patients saved from irreversible blindness by screening (①*⑤) | ⑦ Average life expectancy | ⑧ Minimum average yearly per capita income [CNY (US dollars)] | ⑨ Average yearly per capita income for the blind(estimated 1/5 of the average) [CNY (US dollars)]（⑧*1/5） |
⑩ Indirect benefit ⑥*⑦*(⑧‐⑨) [CNY (US dollars)] |
Gross benefit [CNY (US dollars)] |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Familial exudative vitreoretinopathy | 283 | 15 000 (2142.86) | 50 000 (7142.86) | 9 905 000 (1 415 000) | 5% | 14 | |||||
| Retinoblastoma | 5 | 30 000 (4285.71) | 150 000 (21428.57) | 600 000 (85714.29) | 90% | 4 | |||||
| Retinitis | 14 | 5000 (714.29) | 20 000 (2857.14) | 210 000 (30 000) | 50% | 7 | |||||
| Subtotal | 10 715 000 (15.0714.29) | 25 | 70 | 28 228 (4032.57) | 5645.6 (1128.12) | 40546699.2 (5792385.6) | 51261699.2 (7323099.89) |